Rituximab biosimilar - Allergan/Amgen

Drug Profile

Rituximab biosimilar - Allergan/Amgen

Alternative Names: ABP 798; APB-798

Latest Information Update: 28 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-Hodgkin's lymphoma; Rheumatoid arthritis
  • Phase Unknown Chronic lymphocytic leukaemia

Most Recent Events

  • 14 Feb 2017 Investigation in Chronic lymphocytic leukaemia (IV) (Amgen pipeline, February 2014)
  • 14 Oct 2014 Phase-III clinical trials in Non-Hodgkin's lymphoma in Spain (IV)
  • 26 Aug 2014 Phase-III clinical trials in Rheumatoid arthritis in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top